Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch study from nevirapine immediate-release to extended-release in virologically suppressed adults with HIV-1
2008-004681-55Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nevirapine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Proportion of sustained virologic response through Week 24. Started Sep 2008; status: completed.
02
Drugs
nevirapine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2008-004681-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004681-55.